Form 4 for RLAY Relay Therapeutics, Inc.
Accepted 2026-05-14 18:44:36 ET · period of report 2026-05-14 · accession 0001193125-26-224545 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-14 18:44 | 2026-05-14 | RLAY | Catinazzo Thomas | CFO | S - Sale | $12.86 | -17.7K | 195.2K | -8% | -$227.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-14 | S | D | 17,717 | $12.86 | 195,178 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $12.67 to $13.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 9,807 shares underlying restricted stock units. |